(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 131.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.56%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.83%.
X4 Pharmaceuticals's revenue in 2026 is $9,014,000.On average, 5 Wall Street analysts forecast XFOR's revenue for 2026 to be $872,268,549, with the lowest XFOR revenue forecast at $665,519,775, and the highest XFOR revenue forecast at $1,000,260,376. On average, 5 Wall Street analysts forecast XFOR's revenue for 2027 to be $881,889,158, with the lowest XFOR revenue forecast at $600,816,464, and the highest XFOR revenue forecast at $1,089,392,489.
In 2028, XFOR is forecast to generate $12,536,030,795 in revenue, with the lowest revenue forecast at $7,117,364,260 and the highest revenue forecast at $18,182,950,995.